Consolidated Statements of Cash Flows (USD $)	3 Months Ended		163 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Cash flows from operating activities:
Net loss	$ (491,844)	$ (407,678)	$ (39,413,458)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	801	122	23,494
Gain on sale of furniture and equipment	0	0	(2,200)
Stock-based compensation	11,730	57,291	2,774,391
Common stock issued for services rendered	0	27,450	527,113
Common stock issued for debt issuance cost	0	0	177,086
Notes payable issued for intangibles expensed as research and development	0	0	150,000
Note payable issued for interest	0	0	1,000
Convertible note issued for services rendered	0	0	2,700
Warrants issued for services	0	0	683,370
Warrants issued for debt issuance cost	0	0	1,782,828
Warrants issued for early warrant exercise incentive	0	0	2,727,103
Units issued for interest	0	0	8,700
Units issued for debt extinguisment	0	0	870,981
Amortization of original issue discount on debt	0	7,241	2,675,348
Amortization of debt issuance costs	159,861	82,273	3,995,879
Bargain conversion option added to note payable- related party for debt extinguishment	0	0	48,214
Write-off debt issuance cost for debt extinguishment	0	0	42,797
Write-off of deferred offering cost	0	0	59,696
License rights expensed as research and development, paid by issuance of common stock to CS Medical Technologies, LLC	0	0	475,000
License rights expensed as research and development, paid by issuance of common stock to Profile, LLC	0	0	1,713,600
Changes in operating assets and liabilities:
Prepaid expenses	23,890	24,427	(52,251)
Accounts payable	93,240	51,453	1,119,023
Accrued development expense	(42,875)	0	2,537,510
Accrued expenses	162,948	108,735	1,402,876
Net cash used in operating activities	(82,249)	(48,686)	(15,669,200)
Cash flows from investing activities:
Purchases of equipment and furniture	0	0	(46,325)
Deposit into a restricted cash account	(50,000)	0	(94,214)
Withdrawal from a restricted cash account	0	0	44,214
Net cash used in investing activities	(50,000)	0	(96,325)
Cash flows from financing activities:
Proceeds of note payable, bank	0	0	700,000
Payments of note payable, bank	(50,005)	(200,000)	(1,750,005)
Proceeds of notes payable	0	40,000	1,220,100
Payment of notes payable	(16,588)	(16,544)	(1,797,210)
Proceeds of notes payable - related party	0	0	1,346,596
Payments of notes payable - related party	0	0	(289,300)
Proceeds from long-term convertible notes payable and bank debt	0	0	4,357,362
Proceeds from long-term convertible notes payable - related party	0	200,000	1,913,500
Payments on long-term bank debt	0	0	(600,000)
Net proceeds from warrants	0	0	104,500
Proceeds from exercise of warrants	0	0	2,406,788
Payments for debt issuance costs	(2,500)	0	(798,227)
Payment for rescission of common stock	0	0	(100,000)
Payments for offering expenses	0	0	(651,962)
Cost of reverse merger	0	0	(162,556)
Advances from related parties	78,341	0	78,341
Proceeds from debt subscription agreement	50,000	0	50,000
Net proceeds from issuance of common stock	0	0	9,737,756
Net cash provided by financing activities	59,248	23,456	15,765,683
Net increase (decrease) in cash	(73,001)	(25,230)	158
Cash, beginning of the period	73,159	25,843	0
Cash, end of the period	$ 158	$ 613	$ 158